The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Your healthcare provider will start you on a lower weekly dose and gradually increase it over time. If you’ve been hearing a lot about GLP-1 receptor agonists like semaglutide, you’re not alone.

The participants were divided into two groups, with half receiving weekly low-dose injections of semaglutide (Ozempic and Wegovy), a GLP-1 agonist, and the other half getting a placebo shot.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs ... The company is expected to have 1.6 times as many incretin saleable doses in the first half of this year compared to ...